Stay invested in Strides Shasun, says Sharmila Joshi

Sharmila Joshi of sharmilajoshi.com told CNBC-TV18, "My advice on Strides Shasun is hold. They sold their India branded business to Eris Lifescience recently and they have sold another vertical indicating that they have taken sort of the issues on board and they are trying to sort of rebuild and rebrand their portfolio and hopefully that will yield results going ahead."

Strides Shasun ended at Rs 828.15, up Rs 0.10, or 0.01 percent on the BSE.